Cervical cancer is the fourth most common cancer in women worldwide. Its statistics reveal a stark divide, where geography and access to care determine outcomes.
Key Takeaways
- FIGO staging for cervical cancer is clinical in 60% of cases worldwide due to resource limits
- In 2022, approximately 660,000 women were diagnosed with cervical cancer worldwide, making it the fourth most common cancer in women globally
- In 2022, an estimated 350,000 women died from cervical cancer worldwide
- Persistent infection with high-risk HPV types, particularly HPV-16 (70% of cases) and HPV-18 (20%), is the primary cause of cervical cancer
- Pap smear screening every 3 years from ages 21-65 reduces lifetime risk by 80-90%
- Concurrent chemoradiation with cisplatin improves 5-year survival by 6-12% vs RT alone (stage IB3-IVA)
Cervical cancer remains largely preventable through regular screening and timely follow up care.
Related reading
01 · Category
Diagnosis and Staging30 stats
01
FIGO staging for cervical cancer is clinical in 60% of cases worldwide due to resource limits
02
HPV genotyping identifies 14 high-risk types, with 16/18 in 70% of squamous cell carcinomas
03
MRI detects parametrial invasion with 85% accuracy in stage IB2+ disease
04
PET-CT upstages 25% of clinically early-stage cervical cancers to metastatic
05
Colposcopic biopsy sensitivity for CIN3 is 91%, specificity 96%
06
Endocervical curettage (ECC) detects occult glandular lesions in 10-15% of cases
07
Stage I cervical cancer comprises 50% of diagnoses in high-resource countries
08
Cone biopsy pathology upgrades 20% of CIN2 to invasive cancer
09
Lymph node metastasis occurs in 15% of stage IA2, 28% IB1, per FIGO 2018
10
Cytology HSIL predicts invasive cancer in 1-5% within 2 years if untreated
11
Ultrasound detects hydronephrosis in 70% of stage IIIB cases
12
HPV E6/E7 mRNA positivity correlates 95% with high-grade dysplasia
13
Stage distribution globally: 20% I, 30% II, 30% III, 20% IV (LMICs higher advanced)
14
Schiller's test (iodine) identifies acetowhite areas in 90% of CIN2+
15
Sentinel lymph node mapping detects metastasis with 92% accuracy vs 81% systematic
16
p16 immunohistochemistry positive in 95% of HPV-associated cancers
17
Cystoscopy mandatory for stage III+ to rule out bladder invasion (10-20%)
18
Adenocarcinoma in situ (AIS) diagnosed by cone in 98% via ECC
19
Microinvasion (IA1) defined as <3mm depth, <7mm width, no LVSI (lymphovascular space invasion)
20
CT detects para-aortic nodes in 20% of stage IIB-III, changing management
21
Ki-67 proliferation index high in 85% of progressing lesions
22
Rectosigmoidoscopy for stage IVA shows bowel involvement in 5-10%
23
HPV DNA in plasma indicates poor prognosis in 70% advanced cases
24
Loop electrosurgical excision procedure (LEEP) adequate for staging in 85% early lesions
25
Stage IIIC defined by node involvement regardless of pelvic disease (IIIC1 pelvic, IIIC2 para-aortic)
26
Biopsy of suspicious nodes confirms metastasis in 90% with imaging positivity
27
Cold knife conization preferred for pregnancy preservation, diagnostic accuracy 95%
28
Radical trachelectomy for fertility: 90% diagnostic accuracy pre-op
29
5-year survival for stage IA1 without LVSI is 99%, IA2 98.7%
30
Type 3 hysterectomy standard for IB2+, with 95% negative margins if adequate
Interpretation
Diagnosis and Staging Interpretation
While our imperfect, resource-limited staging methods bravely attempt to map a cunning disease, the true narrative of cervical cancer is written in a language of viral persistence, microscopic invasion, and sobering survival odds that demand we read between the clinical lines with every tool we have.
02 · Category
Incidence and Prevalence29 stats
01
In 2022, approximately 660,000 women were diagnosed with cervical cancer worldwide, making it the fourth most common cancer in women globally
02
In the United States, about 13,960 new cases of invasive cervical cancer were expected to be diagnosed in 2024 among women
03
Globally, cervical cancer incidence rates are highest in sub-Saharan Africa, with age-standardized rates exceeding 30 per 100,000 women in countries like Eswatini and Malawi
04
In low- and middle-income countries, cervical cancer accounts for 85% of the global burden, with over 500,000 new cases annually
05
Among American Indian and Alaska Native women, the cervical cancer incidence rate is 7.3 per 100,000, higher than the national average of 7.4 per 100,000 from 2017-2021
06
In Europe, the highest cervical cancer incidence rates are in Eastern Europe at 13.3 per 100,000 women (2020 data)
07
In India, there were an estimated 123,907 new cervical cancer cases in 2022, representing 18.3% of all cancers in women
08
In Latin America, countries like Bolivia have age-standardized incidence rates of 36.9 per 100,000 for cervical cancer
09
In the UK, there were 3,236 new cervical cancer cases in 2021, a rate of 9.4 per 100,000 women
10
In Australia, cervical cancer incidence has declined by 5.3% annually since 2006 due to vaccination, with 849 cases in 2021
11
In South Africa, cervical cancer is the second most common cancer in women, with 12,847 new cases in 2022
12
In Brazil, there were 17,049 new cervical cancer cases estimated for 2023
13
Globally, the lifetime risk of developing cervical cancer is about 1.6% for women
14
In the US, Black women have a cervical cancer incidence rate of 7.9 per 100,000 from 2017-2021
15
In China, cervical cancer incidence is rising, with 110,000 new cases in 2022
16
In Nigeria, age-standardized incidence rate for cervical cancer is 24.7 per 100,000 women
17
In Japan, cervical cancer cases increased to 11,000 in 2020, with a rate of 8.7 per 100,000
18
In Mexico, cervical cancer is the second leading cause of cancer death in women, with 4,651 cases in 2020
19
In the Philippines, there were 6,709 new cases in 2022, rate of 13.4 per 100,000
20
In Thailand, incidence rate is 14.5 per 100,000 women, with 5,281 cases in 2022
21
In the US Hispanic population, incidence is 9.9 per 100,000 from 2017-2021
22
In Eastern Asia, lowest incidence at 5.9 per 100,000 due to screening
23
In Vietnam, 25,315 new cases in 2022, highest in Southeast Asia proportionally
24
In Canada, 1,550 new cases expected in 2024, rate declining
25
In France, 3,286 cases in 2018, incidence rate 7.6 per 100,000
26
In Russia, 13,000 new cases annually, rate 12.5 per 100,000
27
In Kenya, incidence rate 40.9 per 100,000, one of the highest globally
28
In the US, overall incidence rate 7.4 per 100,000 women (2017-2021)
29
In Indonesia, 36,817 new cases in 2022
Interpretation
Incidence and Prevalence Interpretation
While a preventable cancer remains the fourth most common global scourge for women, these numbers paint a grim portrait of a world sharply divided by the simple, tragic geography of access to screening and vaccination.
03 · Category
Mortality and Survival26 stats
01
In 2022, an estimated 350,000 women died from cervical cancer worldwide
02
In the US, about 4,130 women were expected to die from cervical cancer in 2024
03
Globally, 90% of cervical cancer deaths occur in low- and middle-income countries
04
The age-standardized mortality rate for cervical cancer is 6.2 per 100,000 women worldwide (2020), highest in Africa at 18.5
05
In the US, the 5-year relative survival rate for localized cervical cancer is 92% (2014-2020)
06
In sub-Saharan Africa, cervical cancer mortality rate exceeds 20 per 100,000 women in many countries
07
In the US, Black women have a mortality rate of 5.7 per 100,000 from cervical cancer (2017-2021), 65% higher than White women
08
Globally, cervical cancer caused 1.9% of all cancer deaths in women in 2020
09
In India, 77,348 cervical cancer deaths estimated in 2022
10
The overall 5-year survival rate for cervical cancer in the US is 66% (2014-2020)
11
In low-income countries, late-stage diagnosis leads to 70-80% mortality within 5 years
12
In the UK, cervical cancer mortality has fallen by 74% since the mid-1980s, to 1.5 per 100,000 in 2021
13
In Brazil, 5,709 deaths from cervical cancer in 2022
14
For regional cervical cancer in the US, 5-year survival is 60%; distant stage 19% (2014-2020)
15
In South Africa, 8,295 deaths in 2022, mortality rate 20.3 per 100,000
16
In Australia, cervical cancer mortality rate is 1.6 per 100,000 (2021), down 42% since 2005
17
Globally, without intervention, cervical cancer deaths projected to rise to 520,000 by 2040
18
In the US, Hispanic women have highest mortality rate at 4.1 per 100,000 (2017-2021)
19
In Nigeria, mortality rate 20.4 per 100,000 women
20
In China, 59,000 cervical cancer deaths in 2022
21
In Mexico, age-standardized mortality 8.9 per 100,000 (2020)
22
In the Philippines, 3,723 deaths in 2022
23
In Vietnam, 14,918 deaths, highest mortality burden in region
24
In Russia, mortality rate 5.9 per 100,000
25
In Kenya, mortality rate 27.5 per 100,000
26
In Canada, 430 deaths expected in 2024
Interpretation
Mortality and Survival Interpretation
Cervical cancer is a death sentence of brutal inequality, where your odds of survival depend less on biology and more on geography, wealth, and the color of your skin, proving that a preventable and treatable disease remains a massive global injustice.
More related reading
04 · Category
Risk Factors and Causes29 stats
01
Persistent infection with high-risk HPV types, particularly HPV-16 (70% of cases) and HPV-18 (20%), is the primary cause of cervical cancer
02
Women with HIV have a 6-fold higher risk of developing cervical cancer due to impaired immune response to HPV
03
Smoking increases cervical cancer risk by 1.5-2.5 times, as tobacco metabolites damage cervical cells and promote HPV persistence
04
Long-term use of oral contraceptives (over 5 years) raises risk by 1.9 times due to hormonal effects on cervical epithelium
05
Having 5 or more lifetime sexual partners increases cervical cancer risk by 2.5-fold compared to one partner
06
Early age at first full-term pregnancy (under 17 years) increases risk by 2.2 times versus age 25+
07
Obesity is associated with a 1.4-2.0 increased risk of cervical cancer adenocarcinoma subtype
08
Chlamydia trachomatis infection doubles the risk of cervical cancer when combined with HPV
09
Immunosuppression from organ transplant increases cervical cancer risk 2-8 times
10
Multiparity (5+ births) raises risk by 1.5-3 times due to repeated cervical trauma
11
Low socioeconomic status correlates with 2-3 times higher risk due to limited screening access
12
Previous squamous intraepithelial lesion (SIL) increases progression risk to cancer by 10-20% if untreated
13
HPV-16 prevalence in cervical cancers is 57.4% globally, varying by region (highest in Africa 74%)
14
DES exposure in utero increases clear cell adenocarcinoma risk by 40-fold, though rare
15
Chronic inflammation from herpes simplex virus type 2 synergizes with HPV to elevate risk 2-fold
16
Genetic factors like HLA alleles modify HPV clearance, increasing risk 1.5-3 times in susceptible individuals
17
Alcohol consumption (heavy) associated with 1.4 relative risk increase
18
Vitamin D deficiency linked to 1.6-fold higher risk via immune modulation
19
Folic acid deficiency promotes HPV integration, raising risk by 2-fold
20
Prior hysterectomy for benign disease reduces risk by 50% if cervix removed
21
In utero radiation exposure elevates risk marginally (1.2-1.5)
22
Beta-carotene deficiency correlates with higher persistence of high-risk HPV
23
Family history of cervical cancer increases risk 1.5-2 times, suggesting heritability
24
IUD use may protect against cervical cancer by 20-30% via local immunity
25
Age at first intercourse under 18 triples risk compared to over 25
26
Inadequate fruit/vegetable intake raises risk 1.4-fold
27
90% of cervical cancers are attributable to persistent HPV infection
28
HPV vaccination reduces risk by 87-97% for HPV16/18-related cancers
29
Coinfection with multiple HR-HPV types increases risk 3-5 fold
Interpretation
Risk Factors and Causes Interpretation
Cervical cancer statistics reveal a sobering conspiracy of biology and circumstance, where the common human papillomavirus exploits any vulnerability—be it a weakened immune system from HIV, the cellular damage from smoking, or even the hormonal shifts from long-term birth control—to transform from a ubiquitous infection into a preventable tragedy.
05 · Category
Screening and Early Detection30 stats
01
Pap smear screening every 3 years from ages 21-65 reduces lifetime risk by 80-90%
02
HPV DNA testing detects high-grade lesions with 96% sensitivity vs 70% for cytology alone
03
In the US, 62% of women aged 21-65 were up-to-date with cervical cancer screening per guidelines (2020)
04
Visual inspection with acetic acid (VIA) has 66-90% sensitivity in low-resource settings
05
Co-testing (HPV + Pap) every 5 years for women 30-65 reduces cancer risk by 95%
06
Globally, only 19% of women in low-income countries were screened for cervical cancer in the past 3 years (2020)
07
Self-collected HPV samples have 91% concordance with clinician-collected for high-risk types
08
In the UK, HPV primary screening increased detection of CIN3+ by 30% vs cytology
09
Liquid-based cytology improves unsatisfactory rates to <1% vs 2-5% conventional Pap
10
Single lifetime screen at age 35 in India reduced mortality by 31% (OSCAR trial)
11
In the US, screening rates are lowest among Hispanic (61%) and uninsured women (52%) aged 21-65
12
HPV mRNA testing for E6/E7 oncogenes has 90% specificity for CIN2+
13
In Australia, organized screening post-vaccination era detects 92% of cancers early
14
Colposcopy with biopsy confirms 95% of high-grade lesions seen visually
15
In low-resource areas, screen-and-treat with cryotherapy prevents 39% of cancers (WHO)
16
US Preventive Services Task Force recommends starting screening at age 21
17
In Europe, opportunistic screening coverage averages 60%, varying from 20-85% by country
18
p16/Ki-67 dual stain has 92% sensitivity and 72% specificity for CIN2+
19
In Brazil, national screening program screens 70% of target women annually
20
Cytology detects 50-70% of CIN3, missing 30-50% detected by HPV test
21
In South Africa, VIA screening coverage is 15%, leading to high late-stage disease
22
Digital colposcopy improves detection accuracy by 20% in primary screening
23
In Canada, 70% of women 25-69 screened in past 3 years (2021)
24
HPV self-sampling increases participation by 20-30% in hard-to-reach groups
25
In India, visual screening twice in lifetime (30 and 38 years) cuts mortality 34%
26
ASCCP guidelines triage HPV+ with cytology ASCUS+ to colposcopy 95% effectively
27
Portable spectroscopy for HPV detection shows 95% accuracy in trials
28
In the US, Pap test specificity is 96.8% for CIN2+
29
Cryotherapy post-screening treats 90% of CIN1-2 successfully in LMICs
30
Cone biopsy (LEEP) confirms diagnosis in 98% of referred cases
Interpretation
Screening and Early Detection Interpretation
While we have the tools to almost eradicate cervical cancer, from the nearly foolproof co-test in wealthy nations to a single vinegar swab in a village, the gap between what works in a trial and who it actually reaches is a global scandal of access and equity.
06 · Category
Treatment, Prevention, and Vaccination25 stats
01
Concurrent chemoradiation with cisplatin improves 5-year survival by 6-12% vs RT alone (stage IB3-IVA)
02
HPV vaccine Gardasil 9 prevents 90% of cervical cancers (types 16,18,31,33,45,52,58)
03
Simple hysterectomy cures 98-100% of stage IA1 without LVSI cases
04
In LMICs, single-dose HPV vaccine shows 84% efficacy against persistent infection
05
Radical hysterectomy for stage IB1: 5-year survival 90-95%, recurrence 5-10%
06
Brachytherapy boost after EBRT increases local control by 20% in stage III
07
Quadrivalent HPV vaccine reduced CIN2+ by 57% in fully vaccinated cohorts
08
Neoadjuvant chemotherapy before surgery for IB2 improves operability in 80%
09
Thermal ablation (cold coagulation) treats CIN2+ with 92% success at 1 year
10
Pembrolizumab + chemo extends OS by 14 months in PD-L1+ advanced disease (KEYNOTE-826)
11
Two-dose HPV schedule for 9-14 year olds provides 100% seroconversion vs three-dose
12
Fertility-sparing radical trachelectomy: 91% pregnancy rate, 2.1% recurrence (stage IA1-IB1)
13
Weekly cisplatin (40mg/m2) standard chemoRT, PFS 68% at 5 years stage IIB-IVA
14
HPV vaccination coverage in US girls 11-12: 60% fully vaccinated (2022)
15
Pelvic lymph node dissection in surgery: reduces recurrence by 15% if positive
16
Tisotumab vedotin doubles response rate to 24% in recurrent disease (innovaTV-301)
17
Global strategy aims to vaccinate 90% girls by 15 years, screen 70% women twice by 35/45, treat 90%
18
Extrafascial hysterectomy post-chemoRT for IB3: complete response 80%
19
Bevacizumab + chemo improves OS by 3.7 months in metastatic (GOG-0240)
20
Loop excision for CIN3: 95% cure rate, recurrence 5% if margins clear
21
Australia on track to eliminate cervical cancer by 2035 with 80% vax coverage
22
Para-aortic RT field if PET+ reduces isolated failure by 50%
23
Condom use reduces HPV transmission by 70%, complementing vaccination
24
Topotecan + cisplatin inferior to cisplatin alone in recurrent (GOG-0179)
25
Cryotherapy single visit cure rate 92% for small CIN2+
Interpretation
Treatment, Prevention, and Vaccination Interpretation
The sharp statistical truth here is that while we have everything from brilliantly simple cures for early-stage cervical cancer to complex treatments offering slim but vital survival extensions for advanced cases, the most powerful and maddeningly underutilized weapon remains a humble vaccine, which could prevent nearly all of this suffering in the first place.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Gabrielle Fontaine. (2026, February 13). Cervical Cancer Statistics. Gitnux. https://gitnux.org/cervical-cancer-statistics
MLA
Gabrielle Fontaine. "Cervical Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/cervical-cancer-statistics.
Chicago
Gabrielle Fontaine. 2026. "Cervical Cancer Statistics." Gitnux. https://gitnux.org/cervical-cancer-statistics.
Sources & references
25 datasets cited across this report · attribution is report-level